

Index

a

- acetonitrile 29–32, 35, 44, 64, 65, 74, 78, 93, 97, 107, 110, 116, 118, 121, 125, 133, 174, 203, 226, 228, 229, 234, 236, 258, 259, 263, 269, 270, 276, 278, 281, 282, 285, 287, 291–295, 297, 298, 300, 301, 306, 319, 345, 346, 347, 369, 372, 379, 381
- acetyl pyridine 147, 148
- achiral separations 90–93
- acidic functional groups 152–153, 255
- acidic pH values 31, 43
- acidity constants
 - acid constant estimation 263
 - influence on peak shape 259–263
 - polarity of acidic or alkaline substances 257–259
 - UV spectra 259
- active pharmaceutical ingredients (API) 108, 255, 278–279
- additives 43–44, 52, 54, 65, 76, 81, 83, 87–90, 93, 96–97, 100, 101, 114, 117–119, 123–126, 135, 151, 182, 184, 190, 236, 292, 294, 319, 320, 363, 368, 370, 372
- advanced thermal equilibration control (ATEC) 356
- Agilent 1100 HPLC system 321
- Agilent 1290 Infinity II Flexible Pump 319
- Agilent InfinityLab Quick Connect UHPLC Column Fittings 314
- Agilent technologies
 - automation 319–321
 - HDR 325–326
 - ISET 326–327
 - laboratories sample throughput
 - alternating column regeneration 316
 - dual needle multisampler 316
 - StreamSelect 316–317
 - modular or stepwise upgrade of existing systems 318
 - multimethod and method development systems 321–322
 - multiwash 317–318
 - online SPE 322–323
 - second chromatographic dimension (2D-LC) 323–324
 - separation performance
 - minimizing the dispersion 314–315
 - zero dead-volume fittings 314
 - SFC-HPLC hybrid system 324–325
- Agilent 1290 Infinity II High Dynamic Range Diode Array Detection (HDR-DAD) Impurity Analyzer Solution 325
- alcohols 121
- aldehydes, hydrate formation of 146–148
- amylose derivatives 131
- analytical procedure lifecycle management (APLM) approach 199, 201
- analytical quality-by-design (AQbD)
 - advantage 375, 377
 - Fusion QbD 377

- analytical target profile (ATP) 201–202, 217
- antibody–drug conjugates (ADCs) 59, 76
- APLM Stage 1 202–204
- APLM Stage 2 199, 202, 214
- assistant AZURA ASM 2.2L 333
- automated method development 49, 180–182, 184–188, 196, 243, 368–374
- automated method scouting (AMS) 368, 370–372
- automatic optimization 180, 181

- b**
- best overall answer (BOA) 378, 381
- Bioinert components 340
- BlendAssist 320
- budesonide 376, 378, 379, 381
- building block phase 245, 248
- butamirate dihydrogen citrate, cough syrup 279, 283, 284

- c**
- carbonyl compounds 147, 271
- cation exchange chromatography (CEX) 74
- computer-assisted method development (CAMD) 180
- charged aerosol detection (CAD) 291, 357, 361
- chemical and enzymatic modifications 57
- chemical oxidation 44
- chemistry system screening 202, 204–207, 377
- chiral chromatography 133
- chiral HPLC and SFC 110, 132–135
- chiral polysaccharide stationary phases 110–113
- chiral separation 88–90, 93, 96, 100, 101, 107–138, 180
- chiral stationary phase (CSP) 88, 96, 107
- chromatographer 89, 98, 147, 163, 180, 194
- chromatographic modes 58, 64, 66, 74, 76, 102, 201
- chromatographic optimization parameters 97
- chromatographic separation
 - conjugated ADC 76
 - mobile phase modifiers 76
 - monoclonal antibody 74
 - protein formulations 74
 - released and labeled *N*-glycans 74
 - size exclusion chromatography 76
- chromatography data system (CDS) 49, 180, 182, 191, 192, 362, 364
- Chromeleon eWorkflows 370
- ChromSwordAuto® 180–182, 184, 332, 370, 372, 373
- coated CSPs 113
- coefficient of variation (VC) 165, 166, 171–175
- coinjection 346–348
- column bleeding 35, 49, 51
- column identification kits 327
- column selection 89, 321, 334, 370
- conjugated antibody–drug conjugates (ADCs) 59, 76
- cosmotropic salinity 33
- critical quality attributes (CQA) 189, 192, 357, 368
- cumulative desirability result 378
- CUP laboratories 239–249
- cyproconazole 119

- d**
- data integrity 200, 216
- design of experiments (DOE) 87, 96, 99, 102, 180, 201, 217, 377, 378
- difluoroacetic acid (DFA) 66
- dimethyl formamide (DMF) 148, 149, 256
- diode array (DAD) 87, 171, 272, 325, 357, 361
- 1,4-dioxane 149
- distance effects 152
- donor–acceptor interactions 142, 146

drug development
 early stages of 185
 late stages of 185
 dual LC mode for operation 357, 369

e

electrospray ionization (ESI) 39, 40, 79,
 100, 287
 Empower Validation Manager 383
 enantiomer separation problems
 135–136
 enantioselective chromatography 108,
 137
 E-phase, or Execute 245
 Erlenmeyer rule 147
 ethers, peroxide formation of 150, 151
 ethyl acetate 113, 121, 125, 149, 255, 291,
 345
 2-ethylpyridine-bonded silica stationary
 phase 90

f

fast chiral separations 136–138
 fit for purpose method 109
 flow injection analysis (FIA) 44
 fluorescence detection (FLD) 74, 78,
 304, 357
 formoterol 376–379, 381
 functional moieties, impact of 142–143
 Fusion QbD 377
 BOA 378, 381
 DOE approach 377, 378
 S-Matrix 383

g

generic methods
 active pharmaceutical ingredients
 278–280
 butamirate dihydrogen citrate, cough
 syrup 279
 highly polar compounds 282
 limits of 279
 MS detection improvement 282
 proteins 282
 strongly nonpolar connections 282

UV detection, deep wavelength range
 282
 gradient delay volume (GDV) adjustment
 356, 359–361
 gradient methods 95, 96, 167, 184, 185,
 269, 283, 295, 372, 382, 383
 gradient separations 42, 74, 78, 167, 168,
 358

h

Hansen-solubility parameters 160, 162
 High-Definition Range (HDR) HPLC
 325
 high-efficiency stationary phases 92
 high performance chromatography 58
 high performance liquid chromatography
 (HPLC)
 acid–base constants 255
 Agilent technologies 313
 avoidance of peak tailing 295–302
 basic functional groups 153–155
 blank samples 287–288
 column dimension and particle sizes
 305–308
 content method 242
 dissolved analytes, stability of 255,
 272–278
 experimental data 226
 intelligent and self-contained 362
 measurement uncertainty and method
 design
 calibration–calibration model
 304–305
 detection 304
 dilutions 303
 internal standards 305
 peak shape/separation 304
 weighing in or measuring 302–303
 multidimensional separation modes
 80
 nonpolar analytes 228
 octanol–water partition coefficient
 254, 255, 263–270
 optimizing sensitivity 79–80
 pH value in 151–152

- high performance liquid chromatography (HPLC) (*contd.*)
 - polar analytes 228–230
 - process control analytics 235–237
 - quality control 234–235
 - research and development 221, 233–234
 - robust approaches 222
 - software assisted automated method development 368–374
 - solubility 252–257
 - speed optimization 77–79
 - task, definition of 252
 - 2D-LC separations 363–368
 - UNTIE® process, CUP laboratories 239
 - UV absorption 255, 270–272
 - UV detection wavelengths 288–291
 - Vanquish Core 356–361
 - Vanquish Flex 357
 - Vanquish Horizon 357
 - high pH reversed-phase (RP)
 - fractionation 81
 - high-pressure proportioning gradient pump (HPG) 357
 - high-resolution accurate mass
 - spectrometers (HRAMS) 47, 356
 - high-resolution/accurate mass (HR/AM)
 - measurements 47, 356
 - host-cell protein (HCP) contaminants 81
 - hybrid modes 7–8
 - hydrogen bonds 26, 27, 91, 94, 134, 142–146, 148, 150, 154, 156, 158–161, 224
 - hydroperoxides 150, 151, 156, 157
 - hydrophilic interaction liquid chromatography (HILIC) 78
 - classification 27
 - free silica phase 26
 - 4-hydroxybenzoic acid 25
 - logD value 23
 - mass spectrometric detection 35
 - neutral stationary phases 27
 - organic solvent 28–31
 - pH value 33–34
 - salts 31–33
 - silica particles 26
 - zwitterionic stationary HILIC phases 28
 - hydrophobic compounds 76, 91
 - 1-hydroxy- and 4-hydroxybenzoic acid 23–25, 31, 32, 34
 - hydroxychloroquine (HCQ) 121
 - hyphenated method 48–49
- i**
- immobilized polysaccharide CSPs 89, 112–127
 - InfinityLab LC Companion 327
 - intelligent peak deconvolution analysis (I-PDeA) 351–353
 - intelligent run control (IRC) 370
 - Intelligent System Emulation Technology (ISET) 326–327
 - interactive forces 141, 142
 - Internet of Things (IoT) 341, 353, 354, 362
 - ion chromatography 23, 24, 240, 338
 - ion source parameters 45
 - isocratic methods 96, 170, 382
 - isocratic separations 168, 294, 361
- k**
- ketones, hydrate formation of 146–148
- l**
- L-ABGA 123
 - laboratory information management system (LIMS) 341
 - limit of quantification (LOQ) 108, 165
 - lincomycin 154, 155
 - liquid chromatography (LC) 39, 57, 200, 375
 - long life and/or easy maintenance pump heads 327
 - loop-based multi-heart-cut 2D-LC 364–366
 - loop-based single-heart-cut 2D-LC 364, 365
 - low-pressure proportioning gradient pump (LPG) 357

low wavelengths
 acids and buffer additives 292–294
 drift at solvent gradients 294–295
 solvents 291–292

m

macrocyclic glycopeptide CSPs 89
 MarvinSketch 263, 270
 mass accuracy 47
 mass spectrometry (MS) 3, 7, 12, 14, 15,
 23–36, 39, 40, 42, 43, 50–54, 58, 76,
 81, 87, 100, 137, 200, 234, 272, 352,
 359, 378
 control software 48
 detection 12–14, 41–43, 47–49, 52, 73,
 79, 81–83, 282, 301, 364, 367, 369,
 382
 methanol 29, 30, 44, 93–95, 97, 101, 110,
 113, 116, 118, 121, 125, 133, 135,
 148, 153, 167, 226, 227, 254–256,
 270, 274, 278, 281, 287, 291–294,
 301, 319, 325, 345, 348, 369, 372
 method development (MD) 3–18, 28, 29,
 39–54, 88, 96, 101, 102, 109,
 179–182, 184–188, 192, 194, 196,
 199–217, 221–231, 235, 236, 239,
 241–245, 248, 249, 252, 253, 272,
 318, 320–322, 337, 350, 351, 359,
 367–383
 method operable design region (MODR)
 199, 208, 213, 217, 375
 method scouting 243–245, 322, 368,
 370–373
 mobile-phase composition (MP) 13, 87,
 90, 93, 95–99, 101, 213, 368
 mobile-phase modifiers 76, 127
 mobile phase production
 buffer solutions preparation of 285
 degassing 287
 filtration of solvents and buffer
 285–287
 reagents 283–285
 solvent measurement 284–285
 vessels and fluid bottles 284
 mobile-phase viscosity 78, 94

monoclonal antibodies (mAbs) 57, 74,
 78, 81, 82, 179–196, 200, 358
 monovalent ions 52
 Monte Carlo simulation 210–213
 Monte Carlo optimization procedure
 186
 multidimensional separation modes
 80–81
 multivariate curve resolution-alternating
 least squares (MCR-ALS) 351

n

neutral stationary phases 27
 Nexera system 243, 342, 349
 noise reduction 171
 normal-phase (NP) separation 9, 109,
 113, 325

o

octanol–water partition coefficient 142,
 157–160, 162, 254, 255, 263–270
 one factor at a time (OFAT) 99, 375
 1D method 11, 12
 Online SPE 318, 322–323
 optimization, HPLC
 assistant AZURA ASM 2.2L 333
 automatic method optimization and
 column screening 334–335
 Bioinert components 340
 catalogue of measures 331
 chemical resistance of wetted
 components 338–340
 device level 332–333
 equipment level 330
 fractionation 335–336
 individual optimizations, assistant
 334
 Internet of Things (IoT) 341
 material certification 340
 method levels 330
 outcomes and improvements 329
 peak recycling 335–336
 personnel level 331–332
 purification 336–337
 sample preparation 335–336

optimization, HPLC (*contd.*)
 software 340–341
 specification sheet 329–331
 time-consuming method optimization 332
 wetted vs. dry components 337–338
 optimizing mean performance 207–210
 organic solvents 4, 9, 14, 15, 25, 28–31, 33, 36, 43, 65, 74, 76, 81, 82, 112, 116, 118, 125, 136, 191, 229, 243, 255, 256, 263, 274, 276, 281, 282, 287, 302, 338, 345, 346, 372
 out-of-specification (OOS) 202

p

paracetamol 137, 160–162
 particle size 12, 40–42, 59, 73, 75, 78, 79, 82, 83, 88, 92, 98, 99, 109, 123, 136, 166, 204, 280, 305–308, 323, 356, 361, 382
 peak recycling 335–336
 peak-to-noise ratio 165, 171, 172
 PeakTracker 208
 pharmacopoeia methods 165, 166
 pH dependency 151, 152
 photodiode array (PDA) detector 343, 348–349, 351
 pH value 23, 25, 28, 31, 33–34, 36, 43, 46, 52, 142, 151–152, 155, 156, 167, 221, 257, 258, 260, 261, 263, 272, 273, 283, 285, 298, 301, 338, 377, 379
 Pirok compatibility table 9
 polar organic mode 110, 113–116, 124
 polarity tables 141
 polynuclear nitrogenous aromatics 256
 polysaccharide-based stationary phases 88
 polysaccharide CSPs 88, 110, 127, 129, 133, 135
 POPLC 222, 223
 protein biopharmaceuticals
 high performance chromatography 58–62
 microheterogeneity 57

multidimensional LC approaches 64–66
 nondenaturing LC modes 62–64
 therapeutic proteins and chromatographic methods 58
 protein oxidation 183
 proven acceptable range (PAR) 381
 pumping system 87, 100

q

quality-by-design concepts 49
 quantitative structure–retention relationship (QSRR) modeling 372, 374
 quaternary pumps 203, 204, 319, 320, 323

r

rac-Norketotifen 107, 108
 recombinant monoclonal antibodies (mAbs) 179
 replication strategy 199, 202, 214, 217
 reversed-phase HPLC methods
 automated method development 184–185
 columns screening 185–186
 fine optimization and sample profiling 188
 interaction with instruments 181–182
 performance improvement 194, 196
 rapid optimization mode 186–188
 robustness test 188–189
 sample preparation and HPLC analysis 183–184
 software tools 180, 181
 variables selection 189–190
 reversed phase liquid chromatography (RPLC) 23, 24, 57, 74, 98
 rule of thumb 80, 82, 96, 222, 252, 278, 325

s

sample diluents 74, 97
 sample injector 87

- screening coated and immobilized polysaccharide CSPs
 - in normal phase and polar organic mode 113–116
 - polar organic supercritical fluid chromatography conditions 121–125
 - in reversed-phase mode 116–119
- screening immobilized polysaccharide CSPs
 - in medium-polarity mode 119–122
 - in medium-polarity supercritical fluid chromatography conditions 125–127
- second chromatographic dimension (2D-LC) 323–324
- selective comprehensive mode (sLCxLC) 363
- semipolar phases 26, 27
- separation, HPLC
 - hyphenated method 48–49
 - ion source conditions 44–47
 - mass spectrometry 50–51
 - MS-compatible mobile phase 43
 - MS detection 47–48
 - rapid screening separations 42
 - sample throughput and separation quality 42
 - sensitivity and limit of detection 40–41
 - software-based parameter variation 49–50
- SFC–HPLC hybrid system 325
- Shimadzu LabSolutions Chromatography Software (CDS) 347
- Shimadzu Nexera Method Scouting System 245
- Shimadzu Scouting System 246
- simulated moving bed (SMB) chromatography 336, 337
- single-/multi-heartcut system 52–54
- size exclusion chromatography (SEC) 57, 76, 81, 82
- slit width 343, 348–349
- SmartInject technology 356
- SmartStroke 356
- S-Matrix Fusion QbD® Software 199, 383
 - application to chromatographic separation modes 200
 - non-LC method development procedures 200–201
 - small and large molecule applications 200
 - analytical target profile 201–202
 - APLM Stage 1 202–204
 - APLM Stage 2 214–215
 - chemistry system screening 204–207
 - experimental design and data modeling 201
 - Monte Carlo simulation 210–213
 - optimizing mean performance 207–210
 - USP <1210> 214–216
- software-assisted automated method development 368–374
- software optimization 332, 340–341
- solid phase extraction (SPE) 79
- speed optimization 77–79
- Stage-Gate® model 241
- stationary phase-optimized-selectivity (SOS) 92
- stationary phases (SP) 9, 25–34, 36, 44, 51, 52, 59, 61, 64, 66, 75, 76, 87–93, 95–98, 100–102, 107, 109–113, 124, 127, 129, 132, 135, 136, 138, 141, 151, 157, 166, 167, 204–208, 221, 222, 224, 226, 228, 234–236, 255, 257, 263, 269, 278, 280, 282, 284, 295, 297, 298, 301, 302, 305, 324, 347, 356, 364, 368, 376–378, 383
- statistical process control (SPC) 211
- statistical test planning 49
- StreamSelect 316
- streptomycin 155, 156, 159
- supercritical fluid chromatography (SFC)
 - mobile phases 93
 - optimization parameter 97
 - polysaccharide-based stationary phases 88
 - proportion of cosolvent 94

supercritical fluid chromatography (SFC)
(*contd.*)
SFC-MS coupling 100–101
synthetic polymer CSP 89
two-dimensional chromatography 102
synthetic polymer CSP 89

t

target measurement uncertainty (TMU)
202
Tefzel® 338, 339
Thermo Scientific Vanquish Core systems
362
time-consuming method optimization
332, 352
tolerance interval (TI) 199, 202, 214–217
toluene 23, 24, 111, 161, 162, 256
trap-based single heart-cut 2D-LC for
eluent strength reduction
366–367
trap-based single heart-cut 2D LC-MS
using Vanquish Dual Split Sampler
367–368
trifluoroacetic acid (TFA) 43, 61, 76,
153, 186, 281, 282, 284, 285,
293–295, 297, 298, 301, 356, 379
two-dimensional liquid chromatography
(2D-LC) 13, 363
loop-based multi-heart-cut 2D-LC
364–366
loop-based single-heart-cut 2D-LC
364
trap-based single heart-cut 2D-LC for
eluent strength reduction
366–367
trap-based single heart-cut 2DLC-MS
using Vanquish Dual Split Sampler
367–368
two-dimensional separation 80
choice of mode 5
complex samples 4
comprehensive 2D-LC methods 13
difficult-to-separate samples 3
fixed first dimension conditions 11–13
four 2D separation modes 5–7

hybrid modes 7–8
LC-LC method 14
rules of thumb 13–14
separation goals 4
separation types/mechanisms 8–11
2D-LC separation of surfactants 14–17

u

(U)HPLC performance
advanced peak processing 350–353
auto-diagnostics and auto-recovery
349–350
compressibility settings 345
mixture of water and organic solvent
345, 346
pressure and pressure fluctuations
343
single solvent 345
Internet of Things 353
photodiode array detector, slit width
348–349
solvent composition and injection
volume 346–348
systems 168
ultra-high-performance supercritical fluid
chromatography (UHPSFC) 92
Ultra Low Dispersion Kit 314
unique dual gradient pump (DGP) 357
United States Pharmacopoeia 241
UNTIE® process, CUP laboratories 248
development and optimization method
243–245
existing method, test of 242–243
understanding customer needs
241–242
validation 245–248
UNTIE pyramid 240
USP <1210> 199, 214–216
UV cut-off 291, 301
UV or diode-array detection 87

v

Vanquish Core 356–362
Vanquish Duo-based Dual LC concept
358

Vanquish Flex 356–361
Vanquish Horizon 356–361
Vanquish (U)HPLC platform 355, 356,
370, 372
Vanquish Solvent Monitor (VSM)
362
Vanquish User Interface (VUI) 362

variable-wavelength light absorbance
detection (VWD) 357
volatile ionic detergents 44

Z

zero dead-volume fittings 314
zwitterionic stationary HILIC phases 28

